Pharmacokinetics Dynamics & Metabolism

Pharmacokinetics, Dynamics & Metabolism (PDM)

Our PDM group is focused on development of innovative therapies through an improved understanding of targets, pathways and modeling for preclinical efficacy, and discrete toxicity. We will pursue collaborations to enhance physiological relevance of pharmacological endpoints, biomarkers/biomeasures and metabolomics, systems pharmacology/PKPD, quantitative bioanalytics, prediction of transporter-mediated disposition, tissue targeting.

Full complement of drug metabolism assays, including biotransformation and induction capabilities

Ability to conduct a suite of nonclinical studies to develop robust human PK prediction for routine and less common elimination pathways (AO, UGT, GST etc.,)

Integration in vitro and in silico PK data and mechanisms into PB-PK models to predict human plasma-time profiles for small and large molecules

Selection and deselection of monoclonal antibody drug candidates based on PK properties that are predictive of human PK by using a characterized human FcRn transgenic mouse model and allometric scaling